Last reviewed · How we verify
NCT06725550
Integrative Medicine in Pain Management in Sickle Cell Disease, 2.0
NA trial testing needling acupuncture in Sickle Cell Disease in 120 participants. Currently enrolling.
31 August 2029
Quick facts
| Lead sponsor | Indiana University |
|---|---|
| Phase | NA |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | single |
| Primary purpose | treatment |
| Enrollment | 120 |
| Start date | 25 August 2025 |
| Primary completion | 31 August 2029 |
| Estimated completion | 30 August 2030 |
| Sites | 1 location across United States |
Drugs / interventions tested
- needling acupuncture
- laser acupuncture
Conditions studied
- Sickle Cell Disease — all drugs for Sickle Cell Disease →
- Pain — all drugs for Pain →
- Acupuncture — all drugs for Acupuncture →
- Quantitative Sensory Testing — all drugs for Quantitative Sensory Testing →
Sponsor
Indiana University
Who can join
Adults 14 to 80, any sex, with Sickle Cell Disease or Pain. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The proposed research is to determine the clinical efficacy and neurobiological mechanisms of acupuncture analgesia in patients with sickle cell disease.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06725550
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of needling acupuncture
Trials testing the same drug.
- NCT05045820 — Integrative Medicine in Pain Management in Sickle Cell Disease · NA · active not recruiting
Other recruiting trials for Sickle Cell Disease
Currently open trials in the same condition.
- NCT07369024 — Sub-dissociative Dose Ketamine in Treatment of Vaso-occlusive Pain Event in Children and Young Adults · Phase 2 · recruiting
- NCT06016634 — Alendronate for Osteonecrosis in Adults With Sickle Cell Disease · Phase 2 · recruiting
- NCT06260891 — Zinc Supplementation in Sickle Cell Disease: A Precursor to the Think Zinc for Bones Trial · Phase 2 · recruiting
- NCT07222475 — Writing Relaxing Beats in Adolescents Who Have Sickle Cell Disease · NA · recruiting
- NCT07224360 — Safety of Anumigilimab (CSL324) in Adults With Sickle Cell Disease (SCD) · Phase 2 · recruiting
Other Indiana University trials
Trials by the same sponsor.
- NCT07470086 — The Role of Environmental Temperatures in Respiratory Control · NA · not yet recruiting
- NCT07470099 — The Role of Breathing Perception in Respiratory Control · NA · not yet recruiting
- NCT07179952 — Efficacy and Safety of Slow Release Dehydroepiandrosterone (DHEA ) · Phase 2 · not yet recruiting
- NCT07070804 — Maternal Biomarkers and Environmental Contributors to Autism Spectrum Disorders in Children of First-time Mothers · not yet recruiting
- NCT07499583 — Psilocybin Assisted Psychotherapy for Treatment Resistant Depression and Co-occurring Substance Use Disorder · Phase 1, PHASE2 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06725550 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Indiana University
- Last refreshed: 20 October 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06725550.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing